Interspecific competition is thought to be a pervasive force in evolution (29, 30), and we suggest that the pattern we observe across Lakes Victoria and Tanganyika is likely due to competition between Nile perch and cichlid predators.
For nearly half a century, the robust pharyngeal jaws of cichlids, wrasses, and other pharyngognathous fishes have been considered a classic example of evolutionary innovation that opened up new niches through increased trophic flexibility (18) . Although this is almost certainly correct, our results suggest that the innovation involves a major trade-off that severely limits the size of prey that can be eaten, facilitating competitive inferiority in predatory niches and extinction in the presence of a predatory invader lacking the innovation. The evolutionary innovation of pharyngognathy is not a uniformly beneficial trait, but a specialization that can promote competitive exclusion and extinction depending on ecological context and community composition. † Antibodies targeting CTLA-4 have been successfully used as cancer immunotherapy. We find that the antitumor effects of CTLA-4 blockade depend on distinct Bacteroides species. In mice and patients, T cell responses specific for B. thetaiotaomicron or B. fragilis were associated with the efficacy of CTLA-4 blockade. Tumors in antibiotic-treated or germ-free mice did not respond to CTLA blockade. This defect was overcome by gavage with B. fragilis, by immunization with B. fragilis polysaccharides, or by adoptive transfer of B. fragilis-specific T cells. Fecal microbial transplantation from humans to mice confirmed that treatment of melanoma patients with antibodies against CTLA-4 favored the outgrowth of B. fragilis with anticancer properties. This study reveals a key role for Bacteroidales in the immunostimulatory effects of CTLA-4 blockade.
I
pilimumab is a fully human monoclonal antibody (Ab) directed against CTLA-4, a major negative regulator of T cell activation (1), approved in 2011 for improving the overall survival of patients with metastatic melanoma (MM) (2) . However, blockade of CTLA-4 by ipilimumab often results in immune-related adverse events at sites that are exposed to commensal microorganisms, mostly the gut (3). Patients treated with ipilimumab develop Abs to components of the enteric flora (4). Therefore, given our previous findings for other cancer therapies (5), addressing the role of gut microbiota in the immunomodulatory effects of CTLA-4 blockade is crucial for the future development of immune checkpoint blockers in oncology.
We compared the relative therapeutic efficacy of the CTLA-4-specific 9D9 Ab against established MCA205 sarcomas in mice housed in specific pathogen-free (SPF) versus germ-free (GF) conditions. Tumor progression was controlled by Ab against CTLA-4 in SPF but not in GF mice (Fig. 1,  A and B) . Moreover, a combination of broadspectrum antibiotics [ampicillin + colistin + streptomycin (ACS)] (Fig. 1C) , as well as imipenem alone (but not colistin) (Fig. 1C) , compromised the antitumor effects of CTLA-4-specific Ab. These results, which suggest that the gut microbiota is required for the anticancer effects of CTLA-4 blockade, were confirmed in the Ret melanoma and the MC38 colon cancer models ( fig. S1, A and B) . In addition, in GF or ACS-treated mice, activation of splenic effector CD4 + T cells and tumor-infiltrating lymphocytes (TILs) induced by Ab against CTLA-4 was significantly decreased (Fig. 1, D and E, and fig. S1, C to E).
We next addressed the impact of the gut microbiota on the incidence and severity of intestinal lesions induced by CTLA-4 Ab treatment. A "subclinical colitis" dependent on the gut microbiota was observed at late time points (figs. S2 to S5). However, shortly (by 24 hours) after the first administration of CTLA-4 Ab, we observed increased cell death and proliferation of intestinal epithelial cells (IECs) residing in the ileum and colon, as shown by immunohistochemistry using Ab-cleaved caspase-3 and Ki67 Ab, respectively ( Fig. 2A and  fig. S6A ). The CTLA-4 Ab-induced IEC proliferation was absent in RegIIIb-deficient mice ( fig. S6A) . Concomitantly, the transcription levels of Il17a, Ifng, Ido1, type 1 Ifn-related gene products and Ctla4 (but not Il6), which indicate ongoing inflammatory processes, significantly increased by 24 hours in the distal ileum of CTLA-4 Ab-treated mice ( fig. S6 , B to D). Depletion of T cells, including intraepithelial lymphocytes (IELs) (by injection of Abs specific for CD4 and CD8), abolished the induction of IEC apoptosis by CTLA-4-specific Ab ( Fig. 2A) . When crypt-derived three-dimensional small intestinal enteroids (6) were exposed to Tolllike receptor (TLR) agonists (which act as microbial ligands in this assay) and subsequently admixed with IELs harvested from mice treated with Ab against CTLA-4 (but not isotype Ctl), IECs within the enteroids underwent apoptosis (Fig. 2B) . Hence, CTLA-4 Ab compromises the homeostatic IEC-IEL equilibrium, favoring the apoptotic demise of IEC in the presence of microbial products.
To explore whether this T cell-dependent IEC death could induce perturbations of the microbiota composition, we performed highthroughput pyrosequencing of 16S ribosomal RNA (rRNA) gene amplicons of feces. The principal component analysis indicated that a single injection of CTLA-4 Ab sufficed to significantly affect the microbiome at the genus level (Fig. 2C) . CTLA-4 blockade induced a rapid underrepresentation of both Bacteroidales and Burkholderiales, with a relative increase of Clostridiales, in feces ( Fig. 2C and table S1 ). Quantitative polymerase chain reaction (QPCR) analyses targeting the Bacteroides genus and species (spp.) in small intestine mucosa and feces contents showed a trend toward a decreased relative abundance of such bacteria in the feces, which contrasted with a relative enrichment in particular species [such as B. thetaiotaomicron (Bt) and B. uniformis] in the small intestine mucosa 24 to 48 hours after one CTLA-4 Ab injection ( Fig. 2D and fig. S7 ). One of the most regulatory Bacteroides isolates, B. fragilis (Bf) (7) (8) (9) (10) , was detectable by PCR in colon mucosae but was not significantly increased with CTLA-4 Ab ( fig. S7) .
Next, to establish a cause-and-effect relationship between the dominance of distinct Bacteroides spp. in the small intestine and the anticancer efficacy of CTLA-4 blockade, we recolonized ACS-treated and GF mice with several bacterial species associated with CTLA-4 Abtreated intestinal mucosae as well as Bf. ACStreated mice orally fed with Bt, Bf, Burkholderia cepacia (Bc), or the combination of Bf and Bc, recovered the anticancer response to CTLA-4 Ab, contrasting with all the other isolates that failed We analyzed the dynamics of memory T cell responses directed against distinct bacterial species in mice and humans during CTLA-4 blockade. CD4 + T cells harvested from spleens of CTLA-4 Ab-treated mice (Fig. 3C) or from blood taken from individuals with MM or non-small cell lung carcinoma (NSCLC) patients after two administrations of ipilimumab (Fig. 3, D and E, and table S3) tended to recover a T H 1 phenotype (figs. S10 and S11). The functional relevance of such T cell responses for the anticancer activity of CTLA-4 Ab was further demonstrated by the adoptive transfer of memory Bf-specific (but not B. distasonis-specific) T H 1 cells into GF or ACStreated tumor bearers ( Fig. 3F and fig. S12 ), which partially restored the efficacy of the immune checkpoint blocker.
The microbiota-dependent immunostimulatory effects induced by CTLA-4 blockade depended on the mobilization of lamina propria CD11b + DC that can process zwitterionic polysaccharides (9) and then mount interleukin-12 (IL-12)-dependent cognate T H 1 immune responses against Bf capsular polysaccharides (figs. S13 and S14). However, they did not appear to result from TLR2/TLR4-mediated innate signaling (7, 8) in the context of a compromised gut tolerance (figs. S15 to S19).
To address the clinical relevance of these findings, we analyzed the composition of the gut microbiome before and after treatment with ipilimumab in 25 individuals with MM (table  S4) . A clustering algorithm based on genus composition of the stools (12, 13) distinguished three clusters (Fig. 4A and table S5 ) with Alloprevotella or Prevotella driving cluster A and distinct Bacteroides spp. driving clusters B and C (Fig. 4B) . During ipilimumab therapy, the proportions of MM patients falling into cluster C increased, at the expense of those belonging to cluster B (Fig. 4B and fig. S20A ). We next performed fecal microbial transplantation of feces harvested from different MM patients from each cluster, 2 weeks before tumor inoculation into GF mice that were subsequently treated with anti-CTLA-4 Ab. Tumors growing in mice that had been transplanted with feces from cluster C patients markedly responded to CTLA-4 blockade, contrasting with absent anticancer effects in mice transplanted with cluster Brelated feces (Fig. 4C) , normalized to 16S rDNA and to the basal time point (before treatment). Each dot represents one mouse in two gathered experiments. *P < 0.05; **P < 0.01; ***P < 0.001; ns, not significant. that, although bacteria from the Bacteroidales order equally colonized the recipient murine intestine, stools from cluster C (but not A or B) individuals specifically facilitated the colonization of the immunogenic bacteria Bf and Bt (7-10, 14, 15) (Fig. 4D) . Moreover, after CTLA-4 Ab therapy, only cluster C (not A or B) recipient mice had outgrowth of Bf ( fig. S20B) . Note that the fecal abundance of Bf (but not B. distasonis or B. uniformis) negatively correlated with tumor size after CTLA-4 blockade in cluster C-recipient mice (Fig. 4E and fig. S20C ). Hence, ipilimumab can modify the abundance of immunogenic Bacteroides spp. in the gut, which in turn affects its anticancer efficacy.
Finally, intestinal reconstitution of ACS-treated animals with the combination of Bf and Bc did not increase but rather reduced histopathological signs of colitis induced by CTLA-4 blockade (Fig. 3A) . This efficacy-toxicity uncoupling effect was not achieved with vancomycin, which could boost the antitumor effects of CTLA-4 blockade (presumably by inducing the overrepresentation of Bacteroidales at the expense of Clostridiales) but worsened the histopathological score ( fig. S21 ). In support of this notion, Bf maintained its regulatory properties in the context of CTLA-4 blockade ( fig. S22) (7) .
Hence, the efficacy of CTLA-4 blockade is influenced by the microbiota composition (B. fragilis and/or B. thetaiotaomicron and Burkholderiales). S8 ) and its association with Burkholderiales-recognized through the pyrin-caspase-1 inflammasome (17) and synergizing with TLR2/TLR4 signaling pathways ( fig. S15 )-may account for the immunomodulatory effects of CTLA-4 Ab. Future investigations will determine whether a potential molecular mimicry between distinct commensals and/or pathobionts and tumor neoantigens could account for the toxicity and/or efficacy of immune checkpoint blockers. Prospective studies in MM and/or NSCLC may validate the relevance of the enterotypes described herein in the long-term efficacy of immune checkpoint blockers, with the aim of compensating cluster B-driven patients with live and immunogenic or recombinant Bacteroides spp. (18) or fecal microbial transplantation from cluster C-associated stools to improve their antitumor immune responses. MCA205 tumor-bearing GF mice. A representative experiment containing five to six mice per group is shown. *P < 0.05; **P < 0.01; ***P < 0.001; ns, not significant.
Fig. 4. Biological significance of ipilimumab-induced dysbiosis in patients.
The k means clustering algorithm was applied on the basis of genus composition before and during ipilimumab treatment in 25 MM patients, validated using the Calinski-Harabasz index (14) , and showed good performance in recovering three clusters before and after therapy (interclass PCA , normalized to 16S rDNA. No significant difference in the relative abundance of Bf was detectable in the donors of cluster B versus C before colonization (not shown). (E) Spearman correlations between the amount of Bf in stools 15 days after treatment with 9D9 Ab and tumor sizes across cluster B-and C-recipient mice. *P < 0.05; **P < 0.01; ***P < 0.001. Nationale de la Recherche. A.S. was supported by BMSI YIG 2014. F.G. is supported by SIgN core funding. L.Z., M.C., and I.B.G. are all sponsored by Association pour la Recherche contre le Cancer (PGA120140200851). F.C. was supported by INCA-DGOS (GOLD H78008). N.C. was supported by INCA-DGOS (GOLD study; 2012-1-RT-14-IGR-01). L'Oreal awarded a prize to M.V. We are grateful to the staff of the animal facility of Gustave Roussy and Institut Pasteur. We thank P. Gonin, B. Ryffel, T. Angelique, N. Chanthapathet, H. Li, and S. Zuberogoitia for technical help. DNA sequence reads from this study have been submitted to the NCBI under the Bioproject IDPRJNA299112 and are available from the Sequence Read Archive (SRP Study accession SRP065109; run accession numbers SRR2758006, SRR2758031, SRR2758178, SRR2758179, SRR2758180, SRR2758181, SRR2768454, and SRR2768457. T cell infiltration of solid tumors is associated with favorable patient outcomes, yet the mechanisms underlying variable immune responses between individuals are not well understood. One possible modulator could be the intestinal microbiota. We compared melanoma growth in mice harboring distinct commensal microbiota and observed differences in spontaneous antitumor immunity, which were eliminated upon cohousing or after fecal transfer. Sequencing of the 16S ribosomal RNA identified Bifidobacterium as associated with the antitumor effects. Oral administration of Bifidobacterium alone improved tumor control to the same degree as programmed cell death protein 1 ligand 1 (PD-L1)-specific antibody therapy (checkpoint blockade), and combination treatment nearly abolished tumor outgrowth. Augmented dendritic cell function leading to enhanced CD8 + T cell priming and accumulation in the tumor microenvironment mediated the effect. Our data suggest that manipulating the microbiota may modulate cancer immunotherapy.
H
arnessing the host immune system constitutes a promising cancer therapeutic because of its potential to specifically target tumor cells although limiting harm to normal tissue. Enthusiasm has been fueled by recent clinical success, particularly with antibodies that block immune inhibitory pathways, specifically CTLA-4 and the axis between programmed cell death protein 1 (PD-1) and its ligand 1 (PD-L1) (1, 2) . Clinical responses to these immunotherapies are more frequent in patients who show evidence of an endogenous T cell response ongoing in the tumor microenvironment before therapy (3) (4) (5) (6) . However, the mechanisms that govern the presence or absence of this phenotype are not well understood. Theoretical sources of interpatient heterogeneity include host germline genetic differences, variability in patterns of somatic alterations in tumor cells, and environmental differences.
The gut microbiota plays an important role in shaping systemic immune responses (7) (8) (9) . In the cancer context, a role for intestinal microbiota in mediating immune activation in response to chemotherapeutic agents has been demonstrated (10, 11) . However, it is not known whether commensal microbiota influence spontaneous immune responses against tumors and thereby affect the therapeutic activity of immunotherapeutic interventions, such as anti-PD-1/PD-L1 monoclonal antibodies (mAbs).
To address this question, we compared subcutaneous B16.SIY melanoma growth in genetically similar C57BL/6 mice derived from two different mouse facilities, Jackson Laboratory (JAX) and Taconic Farms (TAC), which have been shown to differ in their commensal microbes (12) . We found that JAX and TAC mice exhibited significant differences in B16.SIY melanoma growth rate, with tumors growing more aggressively in TAC mice (Fig. 1A) . This difference was immunemediated: Tumor-specific T cell responses (Fig. 1 , B and C) and intratumoral CD8 + T cell accumulation (Fig. 1D) were significantly higher in JAX than in TAC mice. To begin to address whether this difference could be mediated by commensal microbiota, we cohoused JAX and TAC mice before tumor implantation. We found that cohousing ablated the differences in tumor growth (Fig.  1E ) and immune responses (Fig. 1, F to H) between the two mouse populations, which suggested an environmental influence. Cohoused TAC and JAX mice appeared to acquire the JAX phenotype, which suggested that JAX mice may be colonized by commensal microbes that dominantly facilitate antitumor immunity.
To directly test the role of commensal bacteria in regulating antitumor immunity, we transferred JAX or TAC fecal suspensions into TAC and JAX recipients by oral gavage before tumor implantation ( fig. S1A ). We found that prophylactic transfer of JAX fecal material, but not saline or TAC fecal material, into TAC recipients was sufficient to delay tumor growth ( Fig. 2A) and to enhance induction and infiltration of tumor-specific CD8 + T cells (Fig. 2, B and C, and fig. S1B ), which supported a microbe-derived effect. Reciprocal transfer of TAC fecal material into JAX recipients had a minimal effect on tumor growth rate and antitumor T cell responses (Fig. 2, A to C, and fig.  S1B ), consistent with the JAX-dominant effects observed upon cohousing.
To test whether manipulation of the microbial community could be effective as a therapy, we administered JAX fecal material alone or in combination with antibodies targeting PD-L1 (aPD-L1) to TAC mice bearing established tumors. Transfer of JAX fecal material alone resulted in significantly slower tumor growth (Fig. 2D) , accompanied by increased tumor-specific T cell responses (Fig. 2E) and infiltration of antigen-specific T cells into the tumor (Fig. 2F) , to the same degree as treatment with systemic aPD-L1 mAb. Combination treatment with both JAX fecal transfer and aPD-L1 mAb improved tumor control (Fig. 2D ) and circulating tumor antigen-specific T cell responses (Fig. 2E) , although there was little additive effect on accumulation of activated T cells within the tumor microenvironment (Fig. 2F) . Consistent with these results, aPD-L1 therapy alone was significantly more efficacious in JAX mice compared with TAC mice (Fig. 2G) , which paralleled improved antitumor T cell responses ( fig. S1C ). These data indicate that the commensal microbial composition can influence spontaneous antitumor immunity, as well as a response to immunotherapy with aPD-L1 mAb.
To identify specific bacteria associated with improved antitumor immune responses, we monitored the fecal bacterial content over time of mice that were subjected to administration of fecal permutations, using the 16S ribosomal RNA (rRNA) miSeq Illumina platform. Principal coordinate analysis revealed that fecal samples analyzed from TAC mice that received JAX fecal material gradually separated from samples obtained from shamand TAC feces-inoculated TAC mice over time (P = 0.001 and P = 0.003, respectively, ANOSIM multivariate data analysis) and became similar
